Streetbeat News

Price Targets

MAA

Mid-America Apartment (NYSE:MAA) received mixed analyst ratings over the past three months, with a total of 7 ratings. The sentiment has shifted towards a more neutral stance in the last 30 days. The 12-month price targets show an average of $135.29, indicating a 2.11% increase from the previous target. Analyst actions include maintaining, raising, and lowering ratings and price targets, reflecting their response to market conditions and company performance. MAA, a real estate investment trust, has shown positive revenue growth, impressive net margin, and strong ROE and ROA, despite lagging behind industry peers in revenue growth.

Portfolio Pulse from Benzinga Insights

February 09, 2024 | 5:00 pm

BLZE

B. Riley Securities has reaffirmed its Buy rating on Backblaze (NASDAQ:BLZE) and increased its price target from $9.00 to $11.00. Backblaze's shares have risen 1.49% in the last 24 hours to $8.88. The new price target suggests a potential upside of 23.87%. Backblaze provides cloud storage services, with a significant portion of its revenue coming from the United States.

Portfolio Pulse from Benzinga Insights

February 09, 2024 | 5:00 pm

DOCS

Doximity Inc (NYSE:DOCS), a digital platform provider for U.S. medical professionals, reported a Q3 2024 revenue of $135.3 million, a 17% increase year-over-year, surpassing both consensus and management guidance. Adjusted net income rose to $58.5 million with a margin of 43.2%, and adjusted EPS of $0.29 beat the consensus of $0.23. Adjusted EBITDA was $73.3 million, up 32% Y/Y. The company raised its fiscal year 2024 revenue forecast to $473.3 million-$474.3 million. Wells Fargo analyst Stan Berenshteyn upgraded DOCS's price target from $25 to $27. Shares are up 1.70% at $28.72.

Portfolio Pulse from Vandana Singh

February 09, 2024 | 5:00 pm

FFIV

Recent analysis of F5 (NASDAQ:FFIV) by 8 analysts shows a mix of opinions, with a consensus leaning towards a neutral stance. Over the last three months, ratings have shifted slightly, but remain predominantly indifferent. The average 12-month price target for FFIV has been raised to $201.25, indicating a 15.19% increase from the previous target. This adjustment reflects analysts' growing optimism about the company's future performance. Despite a negative revenue trend and a market capitalization below industry averages, F5's strong net margin and ROA highlight its financial health and efficient asset utilization.

Portfolio Pulse from Benzinga Insights

February 09, 2024 | 5:00 pm

INTR

Goldman Sachs has reaffirmed its Buy rating on Inter & Co (NASDAQ:INTR), raising the price target from $5.80 to $6.50. Despite a slight decline in share price over the last 24 hours, the new target suggests a potential 18.61% increase. Inter & Co, a digital bank, earns most of its revenue from its Banking & Spending segment.

Portfolio Pulse from Benzinga Insights

February 09, 2024 | 5:00 pm

LSPD

Piper Sandler has maintained its Neutral rating on Lightspeed Commerce (NYSE:LSPD) but reduced its price target from $20.00 to $18.00. Despite this, LSPD shares have risen 1.35% in the last 24 hours to $15.00. An increase to the new target price would represent a 20% gain. Lightspeed Commerce offers an omni-channel commerce-enabling SaaS platform, primarily generating revenue from the U.S.

Portfolio Pulse from Benzinga Insights

February 09, 2024 | 5:00 pm

KPRX

HC Wainwright & Co. has maintained its Buy rating for Kiora Pharmaceuticals (NASDAQ:KPRX) and increased its price target from $3.50 to $2.00. Despite a recent 0.84% decrease in share price to $0.66, the new target suggests a potential 202.57% increase. Kiora Pharmaceuticals is a clinical-stage company focusing on eye disease treatments.

Portfolio Pulse from Benzinga Insights

February 09, 2024 | 5:00 pm

SYNA

Craig-Hallum analyst Anthony Stoss downgraded Synaptics (NASDAQ:SYNA) from Buy to Hold and set a price target of $105.

Portfolio Pulse from Benzinga Newsdesk

February 09, 2024 | 4:55 pm

TDG

RBC Capital analyst Ken Herbert has maintained an Outperform rating on TransDigm Group (TDG) and increased the price target from $1150 to $1250.

Portfolio Pulse from Benzinga Newsdesk

February 09, 2024 | 4:48 pm

THC

RBC Capital analyst Ben Hendrix has maintained an Outperform rating on Tenet Healthcare (NYSE:THC) and increased the price target from $97 to $109.

Portfolio Pulse from Benzinga Newsdesk

February 09, 2024 | 4:44 pm